Perioperative Nivolumab Improves EFS in Resectable NSCLC

Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy only.
Medscape Medical News

source https://www.medscape.com/viewarticle/997604?src=rss